1. Home
  2. CMRE vs MESO Comparison

CMRE vs MESO Comparison

Compare CMRE & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Costamare Inc. $0.0001 par value

CMRE

Costamare Inc. $0.0001 par value

HOLD

Current Price

$14.05

Market Cap

1.9B

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$12.28

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMRE
MESO
Founded
1974
2004
Country
Monaco
Australia
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
2010
2005

Fundamental Metrics

Financial Performance
Metric
CMRE
MESO
Price
$14.05
$12.28
Analyst Decision
Strong Buy
Buy
Analyst Count
2
3
Target Price
$20.00
★ $37.00
AVG Volume (30 Days)
★ 347.2K
248.0K
Earning Date
11-03-2026
08-26-2026
Dividend Yield
★ 3.53%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$59.17
Revenue Next Year
N/A
$59.00
P/E Ratio
$5.55
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.45
$11.89
52 Week High
$18.06
$21.50

Technical Indicators

Market Signals
Indicator
CMRE
MESO
Relative Strength Index (RSI) 38.82 34.52
Support Level $13.86 N/A
Resistance Level $15.76 $16.06
Average True Range (ATR) 0.45 0.42
MACD -0.10 -0.10
Stochastic Oscillator 25.12 15.12

Price Performance

Historical Comparison
CMRE
MESO

About CMRE Costamare Inc. $0.0001 par value

Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and others. The company provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.

Share on Social Networks: